If Tedizolid is proven, as it seems to have been, truly better than Zyvox, then this drug will be a blockbuster. Just a matter of time, which seems to be 2nd half 2014 when all the horses will have left the barn.
they left the barn and they are on the track. If TSRX starts working they may get more love from Cramer. They don't seem to be strong in IR/PR, not all that well known and antibiotics is not as sexy in terms of investing as Oncology, so that is a plus for patient, value seeking biotech investors.
It actually has been proven best in it's class See phase lll secondary studies published in March 2013. The results of the pivotal phase III trial ESTABLISH 2 results met primary and both secondary endpoints. I agree marketing will be in full gear within the year.